Core Viewpoint - The announcement by Valiant Biosciences-B (09887.HK) regarding the successful administration of the first patient in the Phase II clinical trial of Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) for first-line treatment of hepatocellular carcinoma marks significant progress in the expansion of its core product indications [1] Group 1: Clinical Trial Details - The Phase II clinical trial is an open-label, multicenter study led by Professor Zhou Jian from Zhongshan Hospital affiliated with Fudan University, currently being conducted in multiple hospitals across the country [1] - The trial aims to evaluate the efficacy and safety of Opalizumab in combination therapy for patients with hepatocellular carcinoma [1] Group 2: Related Events - Valiant Biosciences-B (09887.HK) has been included in the MSCI Global Small Cap Index [1]
维立志博-B(09887.HK)：LBL-024于一线治疗肝细胞癌II期试验的首例患者用药